본문 바로가기
KERD
논문KCI 등재

간이식 환자에서 CMV 항원혈증 검사의 임상적 유용성에 대한 고찰

Usefulness of Cytomegalovirus (CMV) Antigenemia Assay after Liver Transplantation

이지영|이석구|송재훈|이남용|조재원|문치숙|백경란|위유미|손경목|오원섭|기현균
대한감염학회 (The Korean Society Of Infectious Diseases)|2005.08|Infection and Chemotherapy|제37권 제4호|pp. 199-207

1

조회

0

다운로드

3

인용

0

참고문헌

주제분류내과학

초록

목 적 : 본 연구는 간이식 후 발생한 CMV 감염증의 임상적 양상과 진단을 위한 CMV 항원혈증 검사의 진단적인 유용성에 대하여 검토하고자 진행하였다.재료 및 방법 : 후향적인 연구로서 1996년 1월부터 2003년 8월 까지 삼성서울병원 이식외과에서 간이식을 시행한 환자들을 대상으로 의무기록과 검사기록 등에 대하여 검토를 시행하였다. 결 과 : 총 284명의 환자에서 간이식을 시행하였으며 CMV 항체는 공여자는 모두 양성이었으며 수혜자는 272명이 양성이었다(95.4%). 이중 133명의 환자에서 CMV 감염증이 발생하였으며(46.8%) 40명은 증상을 동반한 감염증이 발생하였다(30.1%). 증상을 동반한 환자 중 12명은 특정 장기를 침범하는 CMV 질환이 발생하였다. 9명의 환자를 제외하고 대부분의 감염증은 이식 후 180일 이내에 발생하였다(93.3%). CMV 항원혈증 검사 결과 검사에서 양성을 보인 환자들의 경우 최고치는 평균 19.36개(19.36±37.64/200,000) 였으며 지속기간은 8.72일 이었다(8.72±9.99일). CMV 항원혈증의 최고치와 지속기간은 증상을 동반한 CMV 감염증에서 높았으며(P=0.002) 재발률도 증상을 동반한 환자에서 높았다(P=0.001). CMV 항원혈증 검사의 치료 기준치를 20만개 중 5개 이상에서 양성을 보이는 경우로 한정하였을 때 기존의 3개 이상과 비교할 때 민감도는 유사하였고 특이도는 증가하였다. 결 론:수혜자의 CMV 항체 양성율이 95.4%인 본 연구에서 CMV 감염증 및 CMV 질환의 발생빈도는 각각 46.8%, 4.2% 이었다. CMV 항원혈증 검사의 치료기준치는 20만개 중 5개 이상에서 양성을 보이는 경우로 올리는 것이 민감도와 특이도를 고려하였을 때 더 적절할 것으로 생각된다.

Abstract

Objective : To evaluate the clinical usefulness of cytomegalovirus (CMV) antigenemia assay among liver transplant recipients in Samsung Medical Center. Materials and Methods : All recipients of liver transplantation during the period from Jan. 1996 to Aug. 2003 were enrolled. Medical records and microbiologic data for CMV infections were reviewed retrospectively. Results : All 284 enrolled patients received livers from CMV seropositive donors, and 272 recipients (95.8%) were CMV seropositive before transplantation. One hundred thirty three recipients (46.8%) had evidences of CMV reactivation. Among patients with CMV reactivation, 40 recipients were symptomatic (30.1%) and 12 patients had organ-specific CMV diseases. Most of the CMV infections occurred within 180 days after transplantation except for 9 patients (6.7%). Among the antigenemia positive patients, the mean number of CMV antigen-positive WBC was 19.36 per 200,000 cells (19.36±37.64 cells). The mean duration of CMV antigenemia was 8.72 days (8.72±9.99 days). Peak value of CMV antigenemia was significantly higher in symptomatic patients compared to asymptomatic patients (P=0.002). Duration of CMV antigenemia was significantly longer (P=0.002) in symptomatic patients. If we would use ≥5 cells of CMV antigenemia as a cut-off value sensitivity and specificity for symptomatic CMV infections would be 85% and 50% respectively. Conclusion : About half of the recipients experienced CMV reactivation, mostly within 180 days after liver transplantation. Thirty percents of reactivation were symptomatic. Five cells per 200,000 leukocytes of CMV antigenemia was the best cut-off level for preemptive treatment.

참고문헌 (67)

  1. "Infections after liver transplantation", pp.132~43 (1988)
  2. "Cytomegalovirus infection following liver transplantation Review of the literature", pp.537~49 (1996)
  3. "Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation"
  4. "interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation", pp.302~2 5 (1988)
  5. "Epidemiology of infections after solid-organ transplantation", pp.1~ (2001)
  6. "Infectious Complications after Liver Transplantation according to Donor Comparison between Orthotopic and Living Donor Transplantation", pp.139~47 (2004)
  7. "Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis", pp.1390~78 6 (2004)
  8. "Late cytomegalovirus disease following liver transplantation", pp.861~5 (2003)
  9. "Infection after Adult-to-Adult Living Donor Liver Transplantation", pp.93~105 (2001)
  10. "Cytomegalovirus infection after liver transplantation", pp.93~9 (1998)
  11. "Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients effect of oral ganciclovir", pp.2~10 (2000)
  12. "Prevention of cytomegalovirus disease in recipients of solid-organ transplants", pp.596~603 (2001)
  13. "Infectious disease complications after renal transplantation", pp.221~36 (1993)
  14. "A Survey on the Cytomegalovirus Antibodies in Blood Donors and the Diseased", pp.21~34 (1990)
  15. "Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients transmission by donated organ and the effect of OKT3 antibodies", pp.124~131 (1988)
  16. "OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation", pp.1014~8 (1995)
  17. "A multivariate analysis of risk factors for cytomegalovirus infection in liver transplant recipients", pp.1326~98 32 (1990)
  18. "Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation"
  19. "viral replication after transplantation for fulminant hepatic failure", pp.506~12 (1997)
  20. "Allograft rejection predicts the occurrence of late-onset cytomegalovirus disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir", pp.1461~4 (2001)
  21. "Epidemiology of infections after solid-organ transplantation", pp.1~ (2001)
  22. "Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis", pp.1390~78 6 (2004)
  23. "Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir" (1801)
  24. "Late cytomegalovirus disease following liver transplantation", pp.861~5 (2003)
  25. "Management of cytomegalovirus infection and disease after solid organ transplantation", pp.1~ (2001)
  26. "Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients effect of oral ganciclovir", pp.2~10 (2000)
  27. "Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes", pp.179~88 (1988), Anema J
  28. "Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation-a report of 130 consecutive patients", pp.991~48 5 (1989), Anema J
  29. "Infectious disease complications after renal transplantation", pp.221~36 (1993)
  30. "Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients transmission by donated organ and the effect of OKT3 antibodies", pp.124~131 (1988)
  31. "A longitudinal prospective study of cytomegalovirus pp65 antigenemia in renal transplant recipients"
  32. "OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation", pp.1014~8 (1995)
  33. "Monitoring and diagnosis of cytomegalovirus infection in renal transplantation", pp.1448~57 (1997)
  34. "Direct detection of cytomegalovirus in peripheral blood leukocytes-a review of the antigenemia assay and polymerase chain reaction", pp.~54
  35. "viral replication after transplantation for fulminant hepatic failure", pp.506~12 (1997)
  36. "Allograft rejection predicts the occurrence of late-onset cytomegalovirus disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir", 184, pp.1461~4 (2001)
  37. "Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus infection after liver transplantation", pp.1133~59 8 (1995)
  38. "Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients", 68, pp.1305~11 (1999)
  39. "Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir", 187, pp.1801~8 (2003)
  40. "Management of cytomegalovirus infection and disease after solid organ transplantation", 33, pp.1~ (2001)
  41. "Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors", 61, pp.1659~60 (1996)
  42. "Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients", 68, pp.1125~31 (1999)
  43. "Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes", pp.179~88 (1988), Anema J
  44. "Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation-a report of 130 consecutive patients", pp.991~48 5 (1989), Anema J
  45. "Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation", 72, pp.881~5 (2001)
  46. "Diagnostic implications of human cytomegalovirus immediate early-1 and pp67 mRNA detection in whole blood samples from liver transplant patients using nucleic acid sequence-based amplification", 38, pp.4485~91 (2000)
  47. "A longitudinal prospective study of cytomegalovirus pp65 antigenemia in renal transplant recipients"
  48. "Monitoring and diagnosis of cytomegalovirus infection in renal transplantation", 8, pp.1448~57 (1997)
  49. "Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation", 355, pp.2032~6 (2000), Sabin CA
  50. "Diagnostic value of monitoring human cytomegalovirus late pp67 mRNA expression in renal-allograft recipients by nucleic acid sequence-based amplification", 36, pp.1341~6 (1998)
  51. "Direct detection of cytomegalovirus in peripheral blood leukocytes-a review of the antigenemia assay and polymerase chain reaction", pp.~54
  52. "Prospective evaluation of the clinical utility of different methods for the detection of human cytomegalovirus disease after liver transplantation", 4, pp.1331~7 (2004)
  53. "Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus infection after liver transplantation", 59, pp.1133~8 (1995)
  54. "Evaluation of the COBAS AMPLICOR CMV MONITOR Test for detection of viral DNA in specimens taken from patients after liver transplantation", pp.600~6 (2000)
  55. "Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients", 68, pp.1305~11 (1999)
  56. "Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation", pp.865~70 (1998)
  57. "Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors", 61, pp.1659~60 (1996)
  58. "Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients", 68, pp.1125~31 (1999)
  59. "Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation", pp.881~72 5 (2001)
  60. "Clinical usefulness of human cytomegalovirus antigenemia assay after kidney transplantation", 72, pp.2151~5 (2003)
  61. "Diagnostic implications of human cytomegalovirus immediate early-1 and pp67 mRNA detection in whole blood samples from liver transplant patients using nucleic acid sequence-based amplification", pp.4485~91 (2000)
  62. "Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation", 355(9220), pp.2032~6 (2000), Sabin CA
  63. "Diagnostic value of monitoring human cytomegalovirus late pp67 mRNA expression in renal-allograft recipients by nucleic acid sequence-based amplification", 36, pp.1341~6 (1998)
  64. "Prospective evaluation of the clinical utility of different methods for the detection of human cytomegalovirus disease after liver transplantation", 4, pp.1331~7 (2004)
  65. "Evaluation of the COBAS AMPLICOR CMV MONITOR Test for detection of viral DNA in specimens taken from patients after liver transplantation", 38, pp.600~6 (2000)
  66. "Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation", 26, pp.865~70 (1998)
  67. "Clinical usefulness of human cytomegalovirus antigenemia assay after kidney transplantation", 75, pp.2151~5 (2003)

관련 논문AI추천

신장이식 환자에서 HCMV 항원혈증 검사의 임상적 유용성김탁, 김성한, 김송철, 김양수, 박관태, 박수길, 성홍섭, 우준희, 이상오, 최상호, 한덕종대한감염학회 · Infection and Chemotherapy2009 · 제41권 제2호C형 간염 간이식 환자에서의 간염 재발 및 처치황신, 김기훈, 문덕복, 박광민, 안철수, 양현승, 오기봉, 이승규, 이영주, 조성훈, 주종우, 하태용대한간학회 · Clinical and Molecular Hepatology2003 · 제9권 제2003호신장이식 이후 약물사용에 따른 Cytomegalovirus 감염의 위험요인 분석곽혜선, 김재연, 박옥선, 박윤희, 송영천, 이영종한국병원약사회 · 병원약사회지2011 · 제28권 제2호간이식 후 발생한 림프구 증식성 질환의 임상적 양상고영혜, 기현균, 김성주, 문치숙, 백경란, 손경목, 송재훈, 오원섭, 위유미, 이석구, 이지영, 조재원대한감염학회 · Infection and Chemotherapy2006 · 제38권 제3호Anti-HBc 양성인 간이식편내 B형간염바이러스 DNA 발현의 변화권준혁, 서경석, 이건욱, 이남준, 장자준, 조재영대한간학회 · Clinical and Molecular Hepatology2006 · 제12권 제2호HBsAb와 HBcAb가 양성인 장기 공여자의 간조직에서 Hepatitis B Virus DNA의 발현김경모, 이승규, 장주영, 정창우대한소아소화기영양학회 · Pediatric Gastroenterology, Hepatology & Nutrition2007 · 제10권 제2호

이 간행물의 다른 논문 (9건)

Quinolone 내성 Escherichia coli에서 Efflux System과 Quinolone 고도 내성과의 연관성 - Real Time PCR과 Nothern Hybridization을 이용한 acrA 유전자의 발현비교김정연, 황병연, 기세윤, 김우주, 김명곤, 정희진, 정혜원, 박윤희, 박정원pp. 185-192다제내성 그람양성 구균에 의한 감염증의 치료에서Tapocin？과 Targocid？의 효능과 안전성에 대한 비교임상연구(제4상)김정연, 김영미, 천병철, 이승은, 정혜원, 김성일, 김민자, 정성주, 박대원, 기세윤pp. 193-1982003년 제주도 세균성이질 환자의 역학적 특성배종면, 고운영, 신상엽pp. 208-220최근 15년간의 비뇨생식기 결핵환자에 대한 고찰장성구, 이선주, 이정원, 김진일, 이충현pp. 221-225Gemella morbillorum에 의한 균혈증 1예박윤수, 조용균, 서일혜, 김민주, 김수연pp. 226-229
원문 보기